Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Intellia Therapeutics (NTLA) Return on Sales (2016 - 2026)

Intellia Therapeutics has reported Return on Sales over the past 12 years, most recently at 0.06% for Q1 2026.

  • Quarterly Return on Sales changed 0.0% to 0.06% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.06% through Mar 2026, up 5.0% year-over-year, with the annual reading at 0.06% for FY2025, 2.0% up from the prior year.
  • Return on Sales was 0.06% for Q1 2026 at Intellia Therapeutics, down from 0.04% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.66% in Q4 2023 and troughed at 0.18% in Q2 2024.
  • The 5-year median for Return on Sales is 0.08% (2022), against an average of 0.04%.
  • Year-over-year, Return on Sales skyrocketed 231bps in 2022 and then tumbled -76bps in 2024.
  • A 5-year view of Return on Sales shows it stood at 0.08% in 2022, then surged by 961bps to 0.66% in 2023, then tumbled by -115bps to 0.1% in 2024, then surged by 59bps to 0.04% in 2025, then plummeted by -58bps to 0.06% in 2026.
  • Per Business Quant, the three most recent readings for NTLA's Return on Sales are 0.06% (Q1 2026), 0.04% (Q4 2025), and 0.08% (Q3 2025).